

Shinsuke Yasuda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/560540/publications.pdf>

Version: 2024-02-01

103
papers

2,135
citations

279798

23
h-index

276875

41
g-index

111
all docs

111
docs citations

111
times ranked

2733
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan. <i>Modern Rheumatology</i> , 2023, 33, 145-153.	1.8	6
2	Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data. <i>Modern Rheumatology</i> , 2023, 33, 302-311.	1.8	4
3	Chondroprotective effects of CDK4/6 inhibition via enhanced ubiquitin-dependent degradation of JUN in synovial fibroblasts. <i>Rheumatology</i> , 2022, 61, 3427-3438.	1.9	7
4	Targeting necroptosis in muscle fibers ameliorates inflammatory myopathies. <i>Nature Communications</i> , 2022, 13, 166.	12.8	28
5	CD34+THY1+ synovial fibroblast subset in arthritic joints has high osteoblastic and chondrogenic potentials in vitro. <i>Arthritis Research and Therapy</i> , 2022, 24, 45.	3.5	7
6	Refractory antiphospholipid antibody syndrome-induced thrombocytopenia successfully treated with belimumab. <i>Lupus</i> , 2022, 31, 624-627.	1.6	3
7	SARS-CoV-2 RNA copy number is a factor associated with the mortality of COVID-19 and improves the predictive performance of mortality in severe cases. <i>Japanese Journal of Infectious Diseases</i> , 2022, , .	1.2	0
8	Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 2118-2131.	7.3	12
9	Efficacy and safety of sodium RISedronate for glucocorticoid-induced Osteoporosis with rheumatoid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial. <i>Modern Rheumatology</i> , 2021, 31, 593-599.	1.8	8
10	Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study. <i>Modern Rheumatology</i> , 2021, 31, 42-52.	1.8	6
11	Azathioprine Monotherapy for the Cases of Immunoglobulin G4-Related Disease With Contraindications to Glucocorticoids. <i>Journal of Clinical Rheumatology</i> , 2021, 27, S327-S330.	0.9	1
12	Predictors associated with clinical improvement of SARS-CoV-2 pneumonia. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 857-863.	1.7	2
13	Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1585-1601.	2.3	5
14	Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 767074.	2.4	20
15	Therapeutic effect of cyclin-dependent kinase 4/6 inhibitor on dermal fibrosis in murine models of systemic sclerosis. <i>Arthritis and Rheumatology</i> , 2021, , .	5.6	2
16	Potential therapeutics for antiphospholipid antibody associated thrombocytopenia: A systematic review and meta-analysis. <i>Modern Rheumatology</i> , 2020, 30, 116-124.	1.8	3
17	Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab: A pilot study. <i>Modern Rheumatology</i> , 2020, 30, 276-281.	1.8	9
18	Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts. <i>Autophagy</i> , 2020, 16, 946-955.	9.1	26

#	ARTICLE	IF	CITATIONS
19	Low C4 as a risk factor for severe neuropsychiatric flare in patients with systemic lupus erythematosus. <i>Lupus</i> , 2020, 29, 1238-1247.	1.6	8
20	Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 581-588.	2.7	11
21	Myofascia-dominant involvement on whole-body MRI as a risk factor for rapidly progressive interstitial lung disease in dermatomyositis. <i>Rheumatology</i> , 2020, 59, 1734-1742.	1.9	13
22	MicroRNA-9 ameliorates destructive arthritis through down-regulation of NF- κ B1-RANKL pathway in fibroblast-like synoviocytes. <i>Clinical Immunology</i> , 2020, 212, 108348.	3.2	23
23	Protective Role of Optineurin Against Joint Destruction in Rheumatoid Arthritis Synovial Fibroblasts. <i>Arthritis and Rheumatology</i> , 2020, 72, 1493-1504.	5.6	10
24	Identification of Compounds With Glucocorticoid Sparing Effects on Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-Like Synoviocytes. <i>Frontiers in Pharmacology</i> , 2020, 11, 607713.	3.5	3
25	Emerging targets for the treatment of lupus erythematosus: There is no royal road to treating lupus. <i>Modern Rheumatology</i> , 2019, 29, 60-69.	1.8	12
26	Right ventricular dimension index by cardiac magnetic resonance for prognostication in connective tissue diseases and pulmonary hypertension. <i>Rheumatology</i> , 2019, 59, 622-633.	1.9	2
27	Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis. <i>Rheumatology International</i> , 2019, 39, 1883-1887.	3.0	5
28	Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1134-1143.	3.8	27
29	Pathogenic roles of anti-C1q antibodies in recurrent pregnancy loss. <i>Clinical Immunology</i> , 2019, 203, 37-44.	3.2	15
30	ABO412â€¦FACTORS THAT AFFECT THE RESPONSE TO TOCILIZUMAB WITH REGARD TO WORK PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: A 2-YEAR FOLLOW-UP OF THE FIRST ACT-SC STUDY. , 2019, , .		0
31	OP0213â€¦MYOFASCIA-DOMINANT: INFLAMMATION DETECTED ON WHOLE BODY MRI PREDICTS RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE IN PATIENTS WITH DERMATOMYOSITIS. , 2019, , .		0
32	A case report dysregulated neutrophil extracellular traps in a patient with propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Medicine (United States)</i> , 2019, 98, e15328.	1.0	6
33	Disseminated Cryptococcosis with Bronchiolitis and Cellulitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 235-236.	5.6	2
34	Clinical significance of antiâ€•DNA /Nâ€•methylâ€•Dâ€•aspartate receptor 2 antibodies in de novo and postâ€•steroid cases with neuropsychiatric systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 443-448.	1.9	4
35	Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis of the femoral head in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 645-649.	1.9	19
36	Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. <i>Rheumatology</i> , 2019, 58, 969-974.	1.9	24

#	ARTICLE	IF	CITATIONS
37	Alternative pathway activation due to low level of complement factor H in primary antiphospholipid syndrome. <i>Thrombosis Research</i> , 2018, 164, 63-68.	1.7	7
38	The role of genetics and epigenetics in rheumatic diseases: are they really a target to be aimed at?. <i>Rheumatology International</i> , 2018, 38, 1333-1338.	3.0	15
39	Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy. <i>Modern Rheumatology</i> , 2018, 28, 879-884.	1.8	14
40	Effect of combined treatment with bisphosphonate and vitamin D on atherosclerosis in patients with systemic lupus erythematosus: a propensity score-based analysis. <i>Arthritis Research and Therapy</i> , 2018, 20, 72.	3.5	7
41	Tocilizumab reduced production of systemic sclerosis-related autoantibodies and anti-cyclic citrullinated protein antibodies in two patients with overlapping systemic sclerosis and rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 248-250.	1.1	8
42	First-Line, Non-Criteria Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti-Î² ₂ -Glycoprotein I Domain I and Anti-Phosphatidylserine/Prothrombin Complex Antibodies Tests. <i>Arthritis Care and Research</i> , 2018, 70, 627-634.	3.4	52
43	Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder. <i>Arthritis and Rheumatology</i> , 2018, 70, 277-286.	5.6	45
44	Clinical significance of plasma presepsin levels in patients with systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2018, 28, 865-871.	1.8	12
45	Interferon-inducible Mx1 protein is highly expressed in renal tissues from treatment-naïve lupus nephritis, but not in those under immunosuppressive treatment. <i>Modern Rheumatology</i> , 2018, 28, 661-669.	1.8	16
46	Mutants of Î² ₂ -glycoprotein I: Their features and potent applications. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 572-590.	3.3	3
47	Anti-TIF1Î³ antibody predicted malignancy of thymic tumor with dermatomyositis as an autoimmune tumor marker. <i>Medicine (United States)</i> , 2018, 97, e13563.	1.0	3
48	Remission of Nephrotic Syndrome After Therapy for Chronic Hepatitis C Virus Infection in a Patient With Systemic Lupus Erythematosus. <i>Annals of Internal Medicine</i> , 2018, 169, 352-353.	3.9	3
49	Ectopic RASGRP2 (CalDAG-GEFI) expression in rheumatoid synovium contributes to the development of destructive arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1765-1772.	0.9	21
50	Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study. <i>Arthritis Research and Therapy</i> , 2018, 20, 151.	3.5	12
51	Decreased Expression of Serine/Arginine-Rich Splicing Factor 1 in T Cells From Patients With Active Systemic Lupus Erythematosus Accounts for Reduced Expression of RasGRP1 and DNA Methyltransferase 1. <i>Arthritis and Rheumatology</i> , 2018, 70, 2046-2056.	5.6	20
52	Prognosis of Neuropsychiatric Systemic Lupus Erythematosus. , 2018, , 169-183.		0
53	Effectiveness of whole-body magnetic resonance imaging for the efficacy of biologic anti-rheumatic drugs in patients with rheumatoid arthritis: A retrospective pilot study. <i>Modern Rheumatology</i> , 2017, 27, 953-960.	1.8	8
54	Maintenance treatment using abatacept with dose reduction after achievement of low disease activity in patients with rheumatoid arthritis (MATADOR) â€“ A prospective, multicenter, single arm pilot clinical trial. <i>Modern Rheumatology</i> , 2017, 27, 930-937.	1.8	6

#	ARTICLE	IF	CITATIONS
55	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1348-1356.	0.9	36
56	Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy. <i>Modern Rheumatology</i> , 2017, 27, 811-819.	1.8	10
57	Takayasu Arteritis with Varied-size Vessel Involvement. <i>Journal of Rheumatology</i> , 2017, 44, 125-126.	2.0	1
58	Decreased haptoglobin levels inversely correlated with pulmonary artery pressure in patients with pulmonary arterial hypertension. <i>Medicine (United States)</i> , 2017, 96, e8349.	1.0	9
59	How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores. <i>Current Rheumatology Reports</i> , 2017, 19, 51.	4.7	20
60	Bi-ventricular interplay in patients with systemic sclerosis-associated pulmonary arterial hypertension: Detection by cardiac magnetic resonance. <i>Modern Rheumatology</i> , 2017, 27, 481-488.	1.8	5
61	Brain MRI abnormalities defined as risks for poor prognosis in lupus patients with acute confusional state: Are they antibody mediated?. <i>Modern Rheumatology</i> , 2017, 27, 191-192.	1.8	0
62	Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide. <i>Internal Medicine</i> , 2017, 56, 445-448.	0.7	8
63	Diversity of borderline pulmonary arterial pressure associated with systemic sclerosis: 3 case series. <i>Modern Rheumatology Case Reports</i> , 2017, 1, 9-14.	0.7	3
64	AAA-ATPase p97 suppresses apoptotic and autophagy-associated cell death in rheumatoid arthritis synovial fibroblasts. <i>Oncotarget</i> , 2016, 7, 64221-64232.	1.8	9
65	Antiphospholipid Antibodies as a Thrombotic Risk Factor in Connective Tissue Diseases and Idiopathic/immune Thrombocytopenic Purpura - Proposal for Altered Cut-off values for Better Prediction. <i>Internal Medicine</i> , 2016, 55, 557-558.	0.7	0
66	Complement and thrombosis in the antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2016, 15, 1001-1004.	5.8	46
67	Significance of fully automated tests for the diagnosis of antiphospholipid syndrome. <i>Thrombosis Research</i> , 2016, 146, 1-6.	1.7	23
68	Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis/pregnancy morbidity in anti-phospholipid syndrome. <i>Rheumatology</i> , 2016, 55, 1403-1411.	1.9	23
69	Post-steroid neuropsychiatric manifestations are significantly more frequent in SLE compared with other systemic autoimmune diseases and predict better prognosis compared with de novo neuropsychiatric SLE. <i>Autoimmunity Reviews</i> , 2016, 15, 786-794.	5.8	23
70	Ribophorin II is involved in the tissue factor expression mediated by phosphatidylserine-dependent antiprothrombin antibody on monocytes. <i>Rheumatology</i> , 2016, 55, 1117-1126.	1.9	2
71	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 75-83.	0.9	94
72	Projectile haemorrhage of a brachial artery in a patient with clinically amyopathic dermatomyositis: Fig. 1. <i>Rheumatology</i> , 2015, 54, 1530-1531.	1.9	5

#	ARTICLE	IF	CITATIONS
73	Successful Colistin Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection Using a Rapid Method for Determination of Colistin in Plasma: Usefulness of Therapeutic Drug Monitoring. <i>Biological and Pharmaceutical Bulletin</i> , 2015, 38, 1430-1433.	1.4	14
74	Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia. <i>Modern Rheumatology</i> , 2015, 25, 609-614.	1.8	6
75	Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. <i>Arthritis Research and Therapy</i> , 2015, 17, 74.	3.5	53
76	Comment on: The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis: reply. <i>Rheumatology</i> , 2015, 54, 1129-1129.	1.9	0
77	Ras Guanine Nucleotide-Releasing Protein 4 Is Aberrantly Expressed in the Fibroblast-like Synoviocytes of Patients With Rheumatoid Arthritis and Controls Their Proliferation. <i>Arthritis and Rheumatology</i> , 2015, 67, 396-407.	5.6	16
78	Decreased expression of Runx1 and lowered proportion of Foxp3 ⁺ CD25 ⁺ CD4 ⁺ regulatory T cells in systemic sclerosis. <i>Modern Rheumatology</i> , 2015, 25, 90-95.	1.8	25
79	Coronary and Mesenteric Involvement in Polyarteritis Nodosa. <i>Arthritis and Rheumatology</i> , 2015, 67, 583-583.	5.6	2
80	Î²2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome. <i>Blood</i> , 2015, 125, 2835-2844.	1.4	61
81	Assessment of Risks of Pulmonary Infection During 12 Months Following Immunosuppressive Treatment for Active Connective Tissue Diseases: A Large-scale Prospective Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 614-622.	2.0	8
82	Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan. <i>Modern Rheumatology</i> , 2015, 25, 854-857.	1.8	11
83	The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. <i>Rheumatology</i> , 2015, 54, 39-44.	1.9	104
84	A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan. <i>Modern Rheumatology</i> , 2015, 25, 858-64.	1.8	4
85	A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan. <i>Modern Rheumatology</i> , 2014, 24, 572-579.	1.8	7
86	Autoantibodies to IgG/HLA class II complexes are associated with rheumatoid arthritis susceptibility. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3787-3792.	7.1	58
87	Comparative analysis of different enzyme immunoassays for assessment of phosphatidylserine-dependent antiprothrombin antibodies. <i>Rheumatology International</i> , 2014, 34, 1225-1230.	3.0	8
88	Long-term outcome in Japanese patients with lupus nephritis. <i>Lupus</i> , 2014, 23, 1124-1132.	1.6	41
89	The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database. <i>Rheumatology International</i> , 2014, 34, 1729-1736.	3.0	14
90	Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody. <i>Rheumatology</i> , 2013, 52, 1775-1784.	1.9	25

#	ARTICLE	IF	CITATIONS
91	Disseminated Intravascular Coagulation in the Presence of Antiphospholipid Antibodies: The Differential Diagnosis from Catastrophic or Microangiopathic Antiphospholipid Syndrome. <i>Internal Medicine</i> , 2013, 52, 169-170.	0.7	2
92	Phospholipid scramblase 1 expression is enhanced in patients with antiphospholipid syndrome. <i>Modern Rheumatology</i> , 2013, 23, 81-88.	1.8	7
93	Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. <i>Arthritis and Rheumatism</i> , 2012, 64, 504-512.	6.7	227
94	Aberrant splicing of the hRasGRP4 transcript and decreased levels of this signaling protein in the peripheral blood mononuclear cells in a subset of patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R154.	3.5	9
95	The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2011, 21, 444-448.	1.8	16
96	Defective Expression of Ras Guanyl Nucleotide-Releasing Protein 1 in a Subset of Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2007, 179, 4890-4900.	0.8	64
97	Butyrate suppresses tumor necrosis factor $\hat{\pm}$ production by regulating specific messenger RNA degradation mediated through acis-acting AU-rich element. <i>Arthritis and Rheumatism</i> , 2005, 52, 2697-2707.	6.7	47
98	Pathogenesis of antiphospholipid antibodies: impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway. <i>Immunobiology</i> , 2005, 210, 775-780.	1.9	40
99	The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti- $\hat{\Delta}$ 2Glycoprotein I antibodies. <i>International Immunology</i> , 2004, 16, 1633-1641.	4.0	115
100	$\hat{\Delta}$ 2-glycoprotein I, anti- $\hat{\Delta}$ 2-glycoprotein I, and fibrinolysis. <i>Thrombosis Research</i> , 2004, 114, 461-465.	1.7	39
101	Nicked $\hat{\Delta}$ 2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. <i>Blood</i> , 2004, 103, 3766-3772.	1.4	54
102	Coagulation and fibrinolytic activities in 2 siblings with $\hat{\Delta}$ 2-glycoprotein I deficiency. <i>Blood</i> , 2000, 96, 1594-1595.	1.4	45
103	$\hat{\Delta}$ 2-glycoprotein I deficiency:. <i>Atherosclerosis</i> , 2000, 152, 337-346.	0.8	77